Nephrotic Syndrome Clinical Trial
Official title:
A Phase 2 Clinical Trial Investigating the Safety and Efficacy of ADX-629 in Subjects With Frequently Relapsing and Steroid-Dependent Nephrotic Syndrome
A Clinical Trial Investigating the Safety and Efficacy of ADX-629 in Subjects with Frequently Relapsing and Steroid-Dependent Nephrotic Syndrome
ADX-629-MCD-001 is a multi-center, two-part, Phase 2 clinical trial designed to evaluate the safety and efficacy of ADX-629 in Subjects with frequently relapsing and steroid-dependent nephrotic syndrome. Study drug will be administered orally every 12 hours (twice daily) to eligible subjects for 90 days. The study will enroll approximately 35 children and adults with nephrotic syndrome who have had a nephrotic relapse in the 6 months prior to screening. The clinical trial is divided into 2 parts: Part 1 (open-label) and Part 2 (double-blinded, randomized). Part 1: Approximately 5 eligible subjects will receive open-label ADX-629 (250 mg) twice daily for 90 days. Part 2: Approximately 30 eligible subjects will be randomized in a 2:1 ratio to receive either ADX-629 (250 mg) or matching placebo twice daily for 90 days. Patients who are interested in participating will be provided detailed information about the study including description of study assessments/procedures, possible side-effects, alternative treatments, and potential benefits. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02238418 -
Efficacy of Usual Vitamin D Supplementation and Its Impact on Children and Adolescents Calciuria.
|
Phase 4 | |
| Completed |
NCT01895894 -
Mycophenolate Mofetil in Pediatric Steroid Dependent Nephrotic Syndrome
|
Phase 4 | |
| Completed |
NCT01411982 -
Role of PACAP in Nehprotic Syndrome
|
N/A | |
| Recruiting |
NCT00308321 -
Long Term Tapering or Standard Steroids for Nephrotic Syndrome
|
Phase 4 | |
| Active, not recruiting |
NCT03326037 -
Study of The Association of Mutations in The NPHS2 Gene and Nephrotic Syndrome in Children and Adults in Middle East
|
||
| Recruiting |
NCT01240564 -
The Nephrotic Syndrome Study Network (NEPTUNE)
|
N/A | |
| Completed |
NCT01252901 -
Registry for Patients With Wilms' Tumor Suppressor Gene 1 (WT1) Mutation Associated Diseases
|
N/A | |
| Completed |
NCT01197040 -
Evaluation of Low Dose Corticosteroids Efficiency, Associated With Myfortic ® in the Treatment of Nephrotic Syndrome
|
Phase 3 | |
| Terminated |
NCT00883636 -
Cardiomyopathy in Steroid-resistant Nephrotic Syndrome: Impact of Focal Segmental Glomerulosclerosis
|
N/A | |
| Completed |
NCT00035334 -
Study of the Safety and Efficacy of NC-503 in Secondary (AA) Amyloidosis
|
Phase 2/Phase 3 | |
| Terminated |
NCT00004466 -
Pilot Study of Atorvastatin in Children With Chronic Hyperlipidemia Secondary to Nephrotic Syndrome
|
Phase 2 | |
| Terminated |
NCT04558892 -
Anti-Xa Activity of Enoxaparin for Prevention of Venous Thromboembolism in Severe Nephrotic Syndrome.
|
Phase 2/Phase 3 | |
| Completed |
NCT02257697 -
A Study to Evaluate the Efficacy and Safety of Mizoribine in the Treatment of Refractory Nephrotic Syndrome
|
Phase 3 | |
| Completed |
NCT00362531 -
Tacrolimus Combined With Prednisone Treatment of Idiopathic Membranous Nephropathy and Nephrotic Syndrome
|
Phase 2/Phase 3 | |
| Completed |
NCT00289328 -
Glucocorticoid-induced Osteopenia in Children
|
N/A | |
| Recruiting |
NCT04759274 -
Diuretic Tuner Clinical Decision Support
|
N/A | |
| Completed |
NCT00001212 -
Drug Therapy in Lupus Nephropathy
|
Phase 2 | |
| Recruiting |
NCT05623033 -
The Predictive Value of Dynamic Changes of CD4+T Lymphocytes in Primary Nephrotic Syndrome With Infection
|
||
| Completed |
NCT03332420 -
The Efficacy of Huaiqihuang Granule in Children With Primary Nephrotic Syndrome
|
||
| Not yet recruiting |
NCT05904197 -
Effectiveness of Educational Gamified Cards About Nephrotic Syndrome
|
N/A |